Alps Advisors Inc. Makes New $124,000 Investment in VBI Vaccines Inc. (NASDAQ:VBIV)

Alps Advisors Inc. bought a new stake in shares of VBI Vaccines Inc. (NASDAQ:VBIVGet Rating) during the second quarter, HoldingsChannel.com reports. The fund bought 153,205 shares of the biopharmaceutical company’s stock, valued at approximately $124,000.

Other hedge funds have also recently modified their holdings of the company. SG Americas Securities LLC boosted its holdings in shares of VBI Vaccines by 91.9% in the second quarter. SG Americas Securities LLC now owns 77,111 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 36,923 shares during the period. E Fund Management Co. Ltd. increased its position in shares of VBI Vaccines by 98.1% during the first quarter. E Fund Management Co. Ltd. now owns 53,148 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 26,320 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of VBI Vaccines by 1,099.6% during the first quarter. Nisa Investment Advisors LLC now owns 126,800 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 116,230 shares in the last quarter. Grimes & Company Inc. increased its position in shares of VBI Vaccines by 19.6% during the first quarter. Grimes & Company Inc. now owns 281,077 shares of the biopharmaceutical company’s stock worth $467,000 after purchasing an additional 46,116 shares in the last quarter. Finally, OLD National Bancorp IN acquired a new position in shares of VBI Vaccines during the second quarter worth $89,000. Institutional investors own 39.96% of the company’s stock.

VBI Vaccines Stock Performance

Shares of VBI Vaccines stock opened at $0.59 on Thursday. The firm has a market capitalization of $152.47 million, a PE ratio of -1.37 and a beta of 1.83. VBI Vaccines Inc. has a twelve month low of $0.55 and a twelve month high of $3.42. The firm’s 50-day moving average price is $0.68 and its 200 day moving average price is $0.83. The company has a current ratio of 2.77, a quick ratio of 2.61 and a debt-to-equity ratio of 0.58.

Wall Street Analyst Weigh In

Separately, Raymond James downgraded VBI Vaccines from a “strong-buy” rating to an “outperform” rating and cut their target price for the company from $5.00 to $2.00 in a research report on Friday, November 11th.

About VBI Vaccines

(Get Rating)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.

Featured Stories

Want to see what other hedge funds are holding VBIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VBI Vaccines Inc. (NASDAQ:VBIVGet Rating).

Institutional Ownership by Quarter for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.